PIRS - Pieris Pharma Annual Revenue Growth (Last Twelve Months)

Pieris Pharmaceuticals (PIRS) is currently undergoing a stage of R&D restructuring and a temporary lull, as confirmed by the annual sales growth rate over a 12-month period on GURU.Markets, where the value 0.00 determines the metric. The company's foundation is its authority in creating anticalin proteins for global partners, while its strategy relies on proprietary engineering to combat cancer and lung pathologies.
Summary analytical data breakdowns for Pieris Pharmaceuticals Inc (PIRS)

Operational efficiency for Pieris Pharmaceuticals (PIRS) depends on overcoming regulatory barriers and ensuring raw material supply stability amid geopolitical turbulence. This metric is calculated as the percentage deviation of current total trailing twelve-month (TTM) revenue from the same period last year, allowing investors to filter out market noise and assess real demand via the TTM revenue growth rate.